<table id="_Refinv-a36608d5-fa95-44ab-bf80-8e4f9ebb" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5. Established and Other Potentially Significant Drug Interactions </caption>
<col width="33%"></col>
<col width="33%"></col>
<col width="33%"></col>
<tfoot>
<tr>
<td align="left" colspan="3" stylecode="Botrule" valign="top">↓= Decreased (induces lamotrigine glucuronidation).</td>
</tr>
<tr>
<td align="left" colspan="3" stylecode="Botrule" valign="top">↑= Increased (inhibits lamotrigine glucuronidation).</td>
</tr>
<tr>
<td align="left" colspan="3" stylecode="Botrule" valign="top">? = Conflicting data.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="center" stylecode="Rrule Botrule Lrule Toprule ">
<paragraph>C<content stylecode="bold">oncomitant Drug</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Effect on Concentration of Lamotrigine or Concomitant Drug</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Clinical Comment</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>↓ lamotrigine </paragraph>
<paragraph>Levonorgestrel ↓</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Decreased lamotrigine concentrations approximately 50%.  </paragraph>
<paragraph>Decrease in levonorgestrel component by 19%.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Carbamazepine and Carbamazepine epoxide</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph> ↓ lamotrigine </paragraph>
<paragraph>?</paragraph>
<paragraph>Carbamazepine epoxide</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Addition of carbamazepine decreases lamotrigine concentration approximately 40%.  May increase carbamazepine epoxide levels.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Lopinavir/ritonavir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>↓ lamotrigine </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Decreased lamotrigine concentration approximately 40%.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Atazanavir/ritonavir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>↓ lamotrigine </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Decreased lamotrigine AUC approximately 32%.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Phenobarbital/Primidone</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph> ↓ lamotrigine</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph> Decreased lamotrigine concentration approximately 40%. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph> Phenytoin </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph> ↓ lamotrigine</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph> Decreased lamotrigine concentration approximately 40%. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph> Rifampin </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>↓ lamotrigine</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph> Decreased lamotrigine concentration approximately 40%. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule ">
<paragraph>Valproate</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule ">
<paragraph> ↑ lamotrigine </paragraph>
<paragraph>? valproate</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule ">
<paragraph>Increased lamotrigine concentrations slightly more than 2-fold.</paragraph>
<paragraph>There are conflicting study results regarding effect of lamotrigine on valproate concentrations: 1) a mean 25% decrease in valproate concentrations in healthy volunteers, 2) no change in valproate concentrations in controlled clinical trials in patients with epilepsy.</paragraph>
</td>
</tr>
</tbody>
</table>